4D Molecular misses earnings by $0.03, revenue beats forecasts
Biotech firm 4D Molecular Therapeutics reported adjusted EPS of $0.67, below expectations, while revenue reached $12.3 million, exceeding analyst estimates.
4D Molecular Therapeutics Inc. (NASDAQ: FDMT) reported adjusted earnings per share (EPS) of $0.67 for the quarter, missing consensus estimates by $0.03, according to Refinitiv data. Revenue for the period totaled $12.3 million, surpassing analyst forecasts of $11.5 million.
The biotechnology company, which develops targeted gene therapies, attributed the EPS miss to higher-than-anticipated research and development expenses. Despite the shortfall, management highlighted progress in its pipeline, including the advancement of its lead candidate, 4D-150, in clinical trials.
Analysts at Jefferies maintained a Buy rating on FDMT with a $28 price target, citing the company’s strong revenue performance and pipeline potential. Shares were down 3.2% in pre-market trading following the release.
4D Molecular has not provided full-year guidance, though executives noted continued investment in R&D to support its gene therapy programs.
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →